Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.
Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab / Conte, Mariasole; Pastore, Serena; Berti, Irene; Taddio, Andrea; Tommasini, Alberto. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 38:4(2020), pp. 760-762.
Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab
Conte, Mariasole
;Pastore, Serena;Taddio, Andrea;Tommasini, Alberto
2020-01-01
Abstract
Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.| File | Dimensione | Formato | |
|---|---|---|---|
|
2496580-2-4.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
4.52 MB
Formato
Adobe PDF
|
4.52 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
11368_2970493_print.pdf
accesso aperto
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Digital Rights Management non definito
Dimensione
5.1 MB
Formato
Adobe PDF
|
5.1 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
